A critique of SAINT II: Wishful thinking, dashed hopes, and the future of neuroprotection for acute stroke

Stroke

Volumn 39, Issue 4, 2008, Pages 1389-1391

  Savitz, Sean I ^a   Schäbitz, Wolf Rüdiger ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Acute stroke; Neuroprotection

Indexed keywords

DISUFENTON SODIUM; FREE RADICAL; NEUROPROTECTIVE AGENT; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE ISCHEMIC STROKE; BLOOD CLOT LYSIS; BRAIN BLOOD FLOW; BRAIN EMBOLISM; CLINICAL TRIAL; DRUG EFFICACY; HEALTH CARE ORGANIZATION; HUMAN; MICROCIRCULATION; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANKIN SCALE; SHORT SURVEY; STROKE; STROKE PATIENT; WHITE MATTER;

ACUTE DISEASE; BENZENESULFONATES; CLINICAL TRIALS AS TOPIC; HUMANS; NEUROPROTECTIVE AGENTS; STROKE; TREATMENT FAILURE;

EID: 41149114028     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.504415     Document Type: Short Survey

References (11)

1. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562-571.
2. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
3. Rogalewski A, Schneider A, Ringelstein EB, Schabitz WR. Toward a multimodal neuroprotective treatment of stroke. Stroke. 2006;37:1129-1136.
4. Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide (generic nxy-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke. 2002;33:1411-1415.
5. Lees KR, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Ashwood T, Hardemark HG, Wasiewski W, Emeribe U, Zivin JA. Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial. Stroke. 2006;37:2970-2978.
6. Muir KW, Lees KR, Ford I, Davis S. Magnesium for acute stroke (intravenous magnesium efficacy in stroke trial): randomised controlled trial. Lancet. 2004;363:439-445.
7. Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjo BK. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab. 1999;19:778-787.
8. Marshall JW, Cummings RM, Bowes LJ, Ridley RM, Green AR. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke. 2003;34:2228-2233.
9. Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol. 2007;205:20-25.
10. Sydserff SG, Borelli AR, Green AR, Cross AJ. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol. 2002;135:103-112.
11. Yoshimoto T, Kristian T, Hu B, Ouyang YB, Siesjo BK. Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia; comparison with cyclosporin A. Brain Res. 2002;932:99-109.